Bioptik Technology (4161) reported revenue of NT$48.1 million for Oct 2026, -20.3% year on year and +0.9% from the previous month. Revenue for Jan–Oct 2026 was NT$704.1 million (+6.4% year on year).
In Oct 2026, it ranked No. 100 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$48.1 million | -20.3% | +0.9% |
| Sep 2026 | NT$47.7 million | -41.1% | -6.2% |
| Aug 2026 | NT$50.9 million | -23.6% | -46.7% |
| Jul 2026 | NT$95.5 million | +41.3% | +23.8% |
| Jun 2026 | NT$77.1 million | -1.3% | -19.7% |
| May 2026 | NT$96 million | +73.8% | +48.8% |
| Apr 2026 | NT$64.5 million | +12.8% | -32.1% |
| Mar 2026 | NT$95.1 million | +40.5% | +74.0% |
| Feb 2026 | NT$54.6 million | -26.6% | -26.8% |
| Jan 2026 | NT$74.6 million | +39.1% | +0.3% |
| Dec 2025 | NT$74.4 million | -7.3% | -26.4% |
| Nov 2025 | NT$101 million | +17.9% | +67.2% |
| Oct 2025 | NT$60.4 million | -2.4% | -25.4% |
| Sep 2025 | NT$81 million | -0.9% | +21.6% |
| Aug 2025 | NT$66.6 million | +6.9% | -1.5% |
| Jul 2025 | NT$67.6 million | +2.2% | -13.5% |
| Jun 2025 | NT$78.1 million | +27.4% | +41.4% |
| May 2025 | NT$55.2 million | -31.2% | -3.4% |
| Apr 2025 | NT$57.2 million | -13.4% | -15.5% |
| Mar 2025 | NT$67.7 million | -4.2% | -9.1% |
| Feb 2025 | NT$74.4 million | +35.6% | +38.7% |
| Jan 2025 | NT$53.6 million | -43.1% | -33.1% |
| Dec 2024 | NT$80.2 million | +17.0% | -6.5% |
| Nov 2024 | NT$85.7 million | -20.6% | +38.5% |
| Oct 2024 | NT$61.9 million | -11.7% | -24.2% |
Jan–Oct 2026 cumulative: NT$704.1 million (+6.4% YoY)
Other Biotech & Medical companies
Compare with peers: Bioptik Technology vs PEC / Bioptik Technology vs Lotus Pharm / Bioptik Technology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16